J&J’s $2 billion play for Californian antibody-drug conjugate (ADC) specialist Ambrx is the largest of the three, and came alongside confirmation of a rumoured takeover of Harpoon Therapeutics ...

Once-daily oral IL-23 inhibitor icotrokinra (formerly JNJ-2113) – which J&J licensed from Protagonist Therapeutics in 2017 – hit both its main efficacy objectives in the ICONIC-LEAD trial ...